Clearmind Medicine Inc. received a notice from Nasdaq for not meeting the minimum bid price requirement of $1.00 per share for 30 consecutive business days. The Company has until June 2, 2026, to regain compliance or face delisting. Clearmind is a biotech company focused on developing psychedelic-derived therapeutics for health issues, with 19 patent families and 31 granted patents. Shares of Clearmind are listed on Nasdaq as “CMND” and the Frankfurt Stock Exchange as “CWY0”. For more information, visit their website or contact Investor Relations at [email protected] or General Inquiries at [email protected].

Read more at GlobeNewswire: Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid